A Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Moderate-to-Severe Uncontrolled Asthma
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Itolizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Proof of concept
- Acronyms EQUIP
- Sponsors Equillium
- 26 Feb 2019 According to an Equillium media release, the company expects to initiate this trial during the second quarter of 2019 and anticipates reporting topline data in the second half of 2020.
- 06 Dec 2018 New trial record
- 15 Nov 2018 According to an Equillium media release, the company expects to initiate this trial in the first half of 2019.